Similar articles

• First-line and second-line antiretroviral therapy.

  Kulwichit W. Kulwichit W. Lancet. 2004 Jul 24-30;364(9431):329-30; author reply 330. doi: 10.1016/S0140-6736(04)16717-2. Lancet. 2004. PMID: 15276389 No abstract available.
• Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.

  van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JM; 2NN Study team. van Leth F, et al. Lancet. 2004 Apr 17;363(9417):1253-63. doi: 10.1016/S0140-6736(04)15997-7. Lancet. 2004. PMID: 15094269 Clinical Trial.
• Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

  Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD; 2NN Study Group. Kappelhoff BS, et al. Antivir Ther. 2005;10(1):145-55. Antivir Ther. 2005. PMID: 15751772 Clinical Trial.
• [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].

  van Leth F, Lange JM. van Leth F, et al. Ned Tijdschr Geneeskd. 2006 Aug 5;150(31):1719-22. Ned Tijdschr Geneeskd. 2006. PMID: 16924943 Review. Dutch.
• Simplification: is it sufficient?

  Cartledge JD. Cartledge JD. HIV Med. 2000;1 Suppl 1:3-6. doi: 10.1046/j.1468-1293.2000.00007.x. HIV Med. 2000. PMID: 11737360 Review. No abstract available.